| 27.93 -2.88 (-9.35%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 42.35 | 1-year : | 49.46 |
| Resists | First : | 36.25 | Second : | 42.35 |
| Pivot price | 29.9 |
|||
| Supports | First : | 18.68 | Second : | 7.82 |
| MAs | MA(5) : | 32.29 |
MA(20) : | 28.96  |
| MA(100) : | 12.39 |
MA(250) : | 0 | |
| MACD | MACD : | 4.1 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 45.3 |
D(3) : | 64.3 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 36.25 | Low : | 2.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OLMA ] has closed above bottom band by 32.9%. Bollinger Bands are 74.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.83 - 32.06 | 32.06 - 32.23 |
| Low: | 26.59 - 26.85 | 26.85 - 27.06 |
| Close: | 27.56 - 27.92 | 27.92 - 28.2 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Fri, 19 Dec 2025
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025 - ts2.tech
Thu, 18 Dec 2025
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.5% - Time to Sell? - MarketBeat
Tue, 16 Dec 2025
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 12-Month High - Time to Buy? - MarketBeat
Mon, 15 Dec 2025
Olema Oncology’s Stock Surge: Analyze Now? - timothysykes.com
Thu, 11 Dec 2025
Olema Pharmaceuticals (OLMA): Reassessing Valuation After Roche’s Phase 3 SERD Success Boosts Palazestrant Expectations - Sahm
Sun, 23 Nov 2025
Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 89.2 (%) |
| Shares Short | 10,810 (K) |
| Shares Short P.Month | 8,370 (K) |
| EPS | -1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.5 % |
| Return on Equity (ttm) | -59.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -15.87 |
| PEG Ratio | 0 |
| Price to Book value | 6.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|